Monoclonal antibody-defined human lung cell surface protein antigens.

Monoclonal antibodies were used to define four distinct antigens present on the surface of human lung tumors. Immunoprecipitation of the four antigens by monoclonal antibodies and sodium dodecyl sulfate:polyacrylamide gel electrophoresis reveals that they have distinct complex structures. Different patterns of expression of these antigens on cells of other than lung tumor origin were detected by the same panel of monoclonal antibodies.

Serological monitoring of vesicular stomatitis New Jersey virus in enzootic regions of Costa Rica.

The activity of vesicular stomatitis viruses was monitored on 3 dairy farms in Costa Rica. Antibody levels were measured and clinical disease monitored in 165 cattle during a 20 month period (1986-1988). Vesicular stomatitis New Jersey (VS NJ) virus was shown to be enzootic on these farms by a 94.2% prevalence of neutralizing antibody; this did not vary significantly between herds. The mean prevalence of antibody to vesicular stomatitis Indiana (VS IN) virus was 15.2%, but was significantly higher in 1 herd. A total of 25 cases (annual incidence rate of 9%) of clinical vesicular stomatitis (VS) was reported. VS NJ virus was identified as the causal agent by detection of VS NJ virus antigens by the complement fixation test. VS NJ virus was isolated in 11 cases. All episodes of disease occurred between November and January, the beginning of the dry season. Most animals maintained stable neutralizing antibody titers throughout the study, and all diseased animals were previously seropositive to VS NJ virus. A total of 31 animals with neutralizing antibodies to VS NJ virus had a VS NJ virus-specific IgM response, and 6 animals had IgM responses that persisted for as long as 6 months. There was no relation between IgM responses and clinical disease occurrence. VS NJ virus persisted predominantly as a subclinical infection in cattle throughout the year in enzootic areas of Costa Rica. The humoral response did not prevent reinfection with VS NJ virus.

Quantifying viral propagation in vitro: toward a method for characterization of complex phenotypes.

For a eukaryotic virus to successfully infect and propagate in cultured cells several events must occur: the virion must identify and bind to its cellular receptor, become internalized, uncoat, synthesize viral proteins, replicate its genome, assemble progeny virions, and exit the host cell. While these events are taking place, intrinsic host defenses activate in order to defeat the virus, e.g., activation of the interferon system, induction of apoptosis, and attempted elicitation of immune responses via chemokine and cytokine production. As a first step in developing an imaging methodology to facilitate direct observation of such complex host/virus dynamics, we have designed an immunofluorescence-based system that extends the traditional plaque assay, permitting simultaneous quantification of the rate of viral spread, as indicated by the presence of a labeled viral protein, and cell death in vitro, as indicated by cell loss. We propose that our propagation and cell death profiles serve as phenotypic read-outs, complementing genetic analysis of viral strains. As our virus/host system we used vesicular stomatitis virus (VSV) propagating in hamster kidney epithelial (BHK-21) and murine astrocytoma (DBT) cell lines. Viral propagation and death profiles were strikingly different in these two cell lines, displaying both very different initial titer and cell age effects. The rate of viral spread and cell death tracked reliably in both cell lines. In BHK-21 cells, the rate of viral propagation, as well as maximal spread, was relatively insensitive to initial titer and was roughly linear over several days. In contrast, viral plaque expansion in DBT cells was contained early in the infections with high titers, while low titer infections spread in a manner similar to the BHK-21 cells. The effect of cell age on infection spread was negligible in BHK-21 cells but not in DBTs. Neither of these effects was clearly observed by plaque assay.

Production of interferon by bovine peripheral blood monocytes infected with bovid herpesvirus 2.

The production of interferon by bovine peripheral blood leukocytes infected with bovid herpesvirus 2 (BHV-2) was investigated in preparation for studying mechanisms of resistance to BHV-2. It was found that bovine peripheral blood monocytes produced high levels of interferon in response to BHV-2 inoculated at a multiplicity of 1. Virus-induced interferon was not stable at pH 2, was destroyed at 56 degrees C or by incubation with trypsin and was active against both vesicular stomatitis virus and BHV-2. Interferon of high specific activity was produced by incubating monocytes for 5 h with BHV-2 in serum-containing medium, replacing the inoculum with serum-free medium for an additional 16 h, and concentrating the serum-free medium by dialysis against dry polyethylene glycol. Interferon concentrations of 40,000 units per mg of protein were readily attained.

Preincubation of bovine blood neutrophils with bovine herpesvirus-1 does not impair neutrophil interaction with Pasteurella haemolytica A1 in vitro.

In this study we examined the direct effects of bovine herpesvirus-1 on the interaction of bovine blood neutrophils with Pasteurella haemolytica A1. Preincubation of neutrophils for approximately 2 h in vitro with BHV-1 at a multiplicity of infection of 5:1 had no effect on neutrophil random migration and directed migration to zymosan-activated bovine serum. Neutrophils also were unimpaired in their ability to ingest and kill P. haemolytica A1. Preincubation of neutrophils with BHV-1 did not elicit an oxidative burst, as measured by luminol-enhanced chemiluminescence, nor did it alter neutrophil chemiluminescence in response to opsonized P. haemolytica A1. Prolonged preincubation with BHV-1 for 18-24 h similarly did not affect neutrophil chemiluminescence in response to opsonized P. haemolytica A1. The susceptibility of neutrophils to the lethal effects of crude P. haemolytica cytotoxin also was unaltered by preincubation with BHV-1. We observed no evidence of BHV-1 replication in bovine neutrophils as determined by indirect immunofluorescence and electron microscopy. Previous reports have indicated that active BHV-1 infection alters certain neutrophil functions and results in hypersusceptibility to pulmonary pasteurellosis. Our results suggest that these effects are unlikely to be mediated directly by BHV-1, but instead may reflect the action of endogenous mediators that are released during active BHV-1 infection.

A monoclonal antibody to inclusion body disease of cranes virus enabling specific immunohistochemistry and competitive ELISA.

Inclusion body disease of cranes (IBDC) herpesvirus kills some infected cranes and persists in convalescent animals. To enable further study and rapid identification of carrier animals, we developed a monoclonal antibody (MAb) to IBDC virus and used it in immunohistochemistry and a competitive enzyme-linked immunosorbent assay (ELISA). We used conventional techniques to make murine MAbs directed against IBDC virus purified from infected duck embryo cells. Hybridomas reacting in an ELISA with IBDC virus but not uninfected duck embryo cells were characterized by radioimmunoprecipitation, in situ immunohistochemistry, and competitive ELISA with neutralizing and nonneutralizing crane sera. MAb 2C11 immunoprecipitated 59-, 61-, and 110-kD proteins from IBDC virus-infected but not uninfected cells and stained glutaraldehyde-fixed IBDC virus plaques but not surrounding uninfected duck embryo cells in vitro. Antibody 2C11 did not react with duck embryo cells infected with falcon herpesvirus, psittacine herpesvirus, infectious laryngotracheitis, pigeon herpesvirus, or duck plague virus. A competitive ELISA using antibody 2C11 identified most sera that were positive in the neutralization test. This antibody will be useful in further characterizing IBDC virus, its pathogenesis, and its natural history.

Vesicular stomatitis.

Vesicular stomatitis is a disease of livestock caused by some members of the Vesiculovirus genus (Family Rhabdoviridae), two of which are called 'vesicular stomatitis virus'. Clinical disease presents as severe vesiculation and/or ulceration of the tongue, oral tissues, feet, and teats, and results in substantial loss of productivity. Except for its appearance in horses, it is clinically indistinguishable from foot-and-mouth disease. Unlike foot-and-mouth disease, it is very infectious for man and can cause a temporarily debilitating disease. Vesicular stomatitis occurs seasonally every year in the southeastern USA, southern Mexico, throughout Central America and in northern South America, and emerges from tropical areas to cause sporadic epidemics in cooler climates during the summer months. Other Vesiculoviruses are endemic in India and Africa. Vesiculoviruses are arthropod-borne and it is possible they are actually well adapted insect viruses that incidentally infect mammals. Vesiculoviruses are relatively simple, having a linear, single stranded, negative sense RNA genome encased in a bullet-shaped virion made from only five proteins. Upon infection of cultured cells, viral products turn off cellular gene expression and seize the entire metabolic potential of the cell. They also depolymerize the cytoskeleton to cause rapid tissue destruction. Virus infection in animals provokes interferon and nitric oxide responses, which quickly control viral replication, and an antibody response that prevents further viral replication. Vesiculovirus genome replication is error-prone, resulting in viral progeny containing many variants. This allows rapid adaptation. Nevertheless, vesicular stomatitis virus genomic sequences appear relatively stable within single endemic areas, and vary progressively on a North-South axis in the Western Hemisphere. Numerous important fundamental discoveries in immunology and virology have come from recent studies of vesicular stomatitis virus. However, these discoveries have not led to a safe and fully effective vaccine for man or beast. In the absence of a vaccine, the continual increase in rapid intercontinental travel, the increase in numbers and concentration of susceptible animals, the plasticity of the viral genome, and the underappreciation of vesiculoviruses as veterinary and zoonotic pathogens by regulators and biomedical researchers, are combining with potentially explosive consequences.

Bovine herpes mammillitis in two New York dairy herds.

Bovine herpes mammillitis was diagnosed in 2 New York dairy herds. Lesions ranged from vesiculation and ulceration of large (up to 10 cm wide) areas of udder and teat skin to single small (2-3 cm wide) plaques of edema. Some lesions resembled "umbilicated pocks" characteristic of cowpox virus infections. Recently freshened heifers were the most severely affected; older cows and heifers with less turgid udders had milder lesions. In 2 cows, incurable mastitis developed. In other cows, the lesions healed by centripetal growth of epidermis into the lesions. Diagnosis was made by isolation of bovid herpesvirus 2 from lesions in both herds and by serum-neutralization testing. Virus isolated from a cow in 1 herd was injected into 9 members of the same herd and may have been responsible for the absence of lesions on these animals; all other members of the herd were affected.

Midgut and salivary gland transcriptomes of the arbovirus vector Culicoides sonorensis (Diptera: Ceratopogonidae).

Numerous Culicoides spp. are important vectors of livestock or human disease pathogens. Transcriptome information from midguts and salivary glands of adult female Culicoides sonorensis provides new insight into vector biology. Of 1719 expressed sequence tags (ESTs) from adult serum-fed female midguts harvested within 5 h of feeding, twenty-eight clusters of serine proteases were derived. Four clusters encode putative iron binding proteins (FER1, FERL, PXDL1, PXDL2), and two clusters encode metalloendopeptidases (MDP6C, MDP6D) that probably function in bloodmeal catabolism. In addition, a diverse variety of housekeeping cDNAs were identified. Selected midgut protease transcripts were analysed by quantitative real-time PCR (q-PCR): TRY1_115 and MDP6C mRNAs were induced in adult female midguts upon feeding, whereas TRY1_156 and CHYM1 were abundant in midguts both before and immediately after feeding. Of 708 salivary gland ESTs analysed, clusters representing two new classes of protein families were identified: a new class of D7 proteins and a new class of Kunitz-type protease inhibitors. Additional cDNAs representing putative immunomodulatory proteins were also identified: 5' nucleotidases, antigen 5-related proteins, a hyaluronidase, a platelet-activating factor acetylhydrolase, mucins and several immune response cDNAs. Analysis by q-PCR showed that all D7 and Kunitz domain transcripts tested were highly enriched in female heads compared with other tissues and were generally absent from males. The mRNAs of two additional protease inhibitors, TFPI1 and TFPI2, were detected in salivary glands of paraffin-embedded females by in situ hybridization.

Heterogeneity of neutralization-related epitopes within a bluetongue virus serotype.

Twenty-four monoclonal antibodies raised against a 1962 Wyoming isolate of blue-tongue virus serotype 17 (BTV 17) were tested against 20 other field isolates of this serotype in a solid-phase radioimmunoassay (RIA), neutralization, and mouse passive protection tests. Of the 21 antibodies that bound in RIA to acetone-fixed BTV-infected cells, 18 bound to cells infected with any of the BTV 17 isolates and 3 detected minor antigenic differences in two isolates. The remaining 3 antibodies, that bound in RIA only to unfixed virus-infected cells detected additional differences. Of the 3 antibodies binding to unfixed virus-infected cells one bound to all but 2 isolates. A second antibody, 6C3A.2, bound only to the Wyoming isolate and passively protected mice against this isolate. The third antibody, 6C2A.4.2, bound to the Wyoming isolate and to 8 isolates from the mid-South U. S., but not to 12 isolates from California. Antibody 6C2A.4.2 neutralized the Wyoming and mid-South isolates to which it bound and passively protected mice against the Wyoming isolate but provided little or no protection against 4 California isolates tested. Polyclonal serum from mice immunized against Wyoming BTV 17 bound in RIA to all BTV 17 isolates and neutralized all isolates. Thus, three neutralization-related antigenic determinants were disclosed, one (perhaps a set) recognized by immune sera on all BTV 17 isolates, a second recognized by antibody 6C2A.4.2 on the Wyoming and 8 mid-South isolates, and a third recognized by antibody 6C3A.2 only on the Wyoming isolate. These differences may be important in selection of virus strains for vaccine development.

Monoclonal antibody analysis of serotype-restricted and unrestricted bluetongue viral antigenic determinants.

Twenty-one monoclonal antibodies that react with bluetongue virus (BTV) and have restricted or unrestricted serotype specificities were identified in culture supernatants of hybridomas derived from lymphocytes of mice immunized with BTV serotype 17. Hybridomas were screened and antibody specificities characterized in a solid-phase radioimmunoassay and by immunoprecipitation with radiolabeled, BTV 17-infected cell lysates. Three general serotype specificities were demonstrated by 13 antibodies that precipitated structural viral protein 9 (VP 9). One antibody precipitated VP 7, a 48,000 dalton nonstructural protein, and reacted in radioimmunoassay with 20 BTV serotypes and Epizootic Hemorrhagic Disease of Deer Virus serotype 1 (EHDV 1), EHDV 2, and Ibaraki virus, but not with uninfected cells. One serotype-specific antibody neutralized infectivity, inhibited hemagglutination by BTV 17, and precipitated VP 2 and VP 3. A second antibody, with restricted serotype specificity, precipitated VP 2 and VP 8. These results confirm those of others (Huismans and Erasmus, Onderstepoort J. Vet. Res. 48, 51-58, 1981) that BTV serotype-specific and neutralizing epitopes are associated with VP 2.

Bovine herpesvirus 1 gIV-expressing cells resist virus penetration.

The interaction of bovine herpesvirus 1 (BHV-1) with the BHV-1 glycoprotein IV (gIV)-expressing cell line D1-1 was examined by radiolabelled virus adsorption assays, in situ autoradiography and electron microscopy. Adsorption of radiolabelled BHV-1 to D1-1 cells was similar to that observed in control cell lines but in situ radiography revealed that virus moved to the nucleus of control but not the gIV-expressing cells. Electron microscopy studies showed that BHV-1 attached to the cell membranes of D1-1 and control cells at 4 degrees C but penetration of virus was observed only in control cells when the temperature was shifted to 37 degrees C. These results provide further evidence that cellular expression of gIV does not prevent viral adsorption, but does prevent the entrance of the virus into the cell.

Temporal control of bovine herpesvirus 1 glycoprotein synthesis.

The gI, gIII, and gIV glycoproteins are major bovine herpesvirus 1 antigens involved in virus neutralization. Results indicate that the gI and gIV glycoproteins were expressed as beta proteins, whereas the gIII glycoprotein was expressed strictly as a gamma protein. These findings suggest that gI and gIV may be superior to gIII as vaccine candidates.

Cellular expression of bovine herpesvirus 1 gD inhibits cell-to-cell spread of two closely related viruses without blocking their primary infection.

Alphaherpesviral glycoprotein D (gD) is a critical component of the cell membrane penetration system. Cells that express gD of herpes simplex virus type 1 (HSV1), pseudorabies virus (PRV), or bovine herpesvirus type 1.1 (BHV1.1) resist infection by the homologous virus due to interference with viral entry at the level of penetration. BHV1.1 gD interferes with the distantly related viruses HSV1 and PRV despite only a 30-40% sequence similarity and the complete absence of antigenic cross-reactivity among the three gDs. The six cysteines that form three intrachain disulfide bonds in HSV1 are also present in PRV and BHV1.1 gD, suggesting structural similarities among the gD homologs. Functional similarities were postulated to be responsible for cross-interference. To test this hypothesis, we constructed a BHV1.1 gD-expressing cell line (MDBKgD) and assessed its resistance to the homologous BHV1.1 and two closely related viruses, BHV1.2 and BHV5. The gDs of these viruses share 98. 3% and 86% amino acid identity with BHV1.1 gD and bound monoclonal antibodies directed against all five neutralizing epitopes mapped on BHV1.1 gD. MDBKgD cells were resistant to BHV1.1 but fully susceptible to BHV1.2 and BHV5 infection as measured by plaque numbers and single cycle growth kinetics. However, all three viruses, but not vesicular stomatitis virus, made smaller plaques on MDBKgD cells than on control cells. These data suggest that gD-mediated interference is expressed both at the level of initial infection and at the level of cell-to-cell spread and that these two levels can be distinguished by using closely related viruses.

Mucosal and systemic immunity to bovine herpesvirus-1 glycoprotein D confer resistance to viral replication and latency in cattle.

Mucosal immunity in the respiratory tract directed against bovine herpesvirus-1 (BHV-1) glycoprotein B forms an effective barrier against BHV-1 replication in cattle. Here we investigated the ability of a second BHV-1 glycoprotein, gD, to engender specific antibodies in nasal secretion and serum and protect against infection. We expected gD to give greater protection than gB because anti-gD antibodies prevent viral penetration into cells at much lower concentrations than anti-gB antibodies. Calves vaccinated once subcutaneously and thrice intranasally with affinity-purified BHV-1 gD had mucosal antibodies and three of five were protected against intranasal challenge by 10(7) p.f.u. of BHV-1. Four of the five vaccinated calves were proven free of BHV-1 latency by the lack of viral shedding following immunosuppression. The putative mucosal adjuvant, cholera toxin B subunit (CTB), did not significantly enhance mucosal immunity or protection against challenge or latency (P0.5) since only 4 of 6 gD plus CTB immunized calves were completely protected. Taken together, these data suggest that BHV-1 gD may be useful in a mucosal vaccine against BHV-1 infection in cattle but is less than totally effective when used alone.

Persistence of vesicular stomatitis virus New Jersey RNA in convalescent hamsters.

Persistence of vesicular stomatitis virus New Jersey (VSV-NJ) was studied in experimentally infected hamsters (Mesocricetus auratus). We used reverse transcription and nested polymerase chain reaction (RT-NPCR) to probe tissues of hamsters inoculated with VSV-NJ Hazelhurst. Viral genomic RNA was detected in the brain, cerebellum, spleen, liver, kidney, and lung 2 months after infection, but only in the central nervous system at 10 and 12 months. Viral messenger RNA was detected in the brain of one hamster at 2 months after infection. Replicative intermediate was detected in the spinal cord of one hamster at 12 months. These results suggest that VSV-RNA persists in animals for long periods following infection, disease, and convalescence. However, infectious virus was not recovered from tissues by conventional serial passages of tissue extracts in Vero cells or by cocultivation.

Passive protection of mice and sheep against bluetongue virus by a neutralizing monoclonal antibody.

A murine hybridoma antibody, 6C2A.4.2, previously characterized as an immunoglobulin G class 2a that binds in radioimmunoassay to bluetongue virus serotype 17 (BTV-17) but not the other 19 BTV serotypes, neutralizes BTV-17, inhibits hemagglutination with BTV-17, and precipitates viral polypeptides 2 and 3 from BTV-17-infected cells, was produced as an ascites in the peritoneal cavities of hybridoma-inoculated mice. This ascitic fluid, but not those containing other, non-neutralizing anti-BTV-17 antibodies of the same isotype, provided serotype-specific passive protection against BTV-17-induced death of neonatal mice. Antibody 6C2A.4.2-containing ascitic fluid was injected intravenously into sheep that were later inoculated with BTV-17. These sheep remained free of clinical signs, did not develop viremia or detectable levels of antibodies reactive in the immunodiffusion test used for routine BTV diagnosis in the United States, and developed only low levels of neutralizing antibodies. Control animals became viremic and developed immunodiffusion test reactions and high levels of neutralizing antibodies during recovery, and two of three had lesions and fevers. These results provide evidence that antibodies directed against a single epitope on BTV-17 can prevent bluetongue disease.

Bovid herpesvirus 2 latency: failure to recover virus from central sensory nerve ganglia.

Latent bovid herpesvirus 2 was sought in sensory ganglia, epithelium and lymph nodes from cattle having antibodies against bovid herpes virus 2. Tissues from eight animals were maintained in vitro as explants for 49-72 days during which all expended media was tested for virus. Three animals were pretreated with corticosteroids prior to slaughter. Infectious bovine rhinotracheitis virus was recovered from one animal, but bovid herpesvirus 2 was not detected.

Passively administered neutralizing monoclonal antibodies do not protect calves against bovine herpesvirus 1 infection.

Monoclonal antibodies specific for defined epitopes on the gI, gIII and gIV envelope glycoproteins of BHV-1 were used individually or in glycoprotein-monospecific pools for passive immunization of young calves. Although serum antibody titres comparable to those found in naturally infected and recovered calves were achieved, passive immunization failed to prevent the growth of BHV-1 in nasal and ocular mucosa and did not decrease the duration of viral shedding.

Bovine herpesvirus 1 U(L)3.5 interacts with bovine herpesvirus 1 alpha-transinducing factor.

The bovine herpesvirus 1 (BHV-1) U(L)3.5 gene encodes a 126-amino-acid tegument protein. Homologs of U(L)3.5 are present in some alphaherpesviruses and have 20 to 30% overall amino acid homology that is concentrated in the N-terminal 50 amino acids. Mutant pseudorabies virus lacking U(L)3.5 is deficient in viral egress but can be complemented by BHV-1 U(L)3.5 (W. Fuchs, H. Granzow, and T. C. Mettenleiter, J. Virol. 71:8886-8892, 1997). The function of BHV-1 U(L)3.5 in BHV-1 replication is not known. To get a better understanding of its function, we sought to identify the proteins that interact with the BHV-1 U(L)3.5 protein. By using an in vitro pull-down assay and matrix-assisted laser desorption ionization mass spectrometry analysis, we identified BHV-1 alpha-transinducing factor (alphaBTIF) as a BHV-1 U(L)3. 5-interacting protein. The interaction was verified by coimmunoprecipitation from virus-infected cells using an antibody to either protein, by indirect immunofluorescence colocalization in both virus-infected and transfected cells, and by the binding of in vitro-translated proteins. In virus-infected cells, U(L)3.5 and alphaBTIF colocalized in a Golgi-like subcellular compartment late in infection. In transfected cells, they colocalized in the nucleus. Deletion of 20 amino acids from the N terminus of U(L)3.5, but not 40 amino acids from the C terminus, abolished the U(L)3.5-alphaBTIF interaction both in vitro and in vivo. The interaction between U(L)3. 5 and alphaBTIF may be important for BHV-1 maturation and regulation of alphaBTIF transactivation activity.